Zhang Yong, Chen Wei, Ji Jun-feng, Wang Zhi-yi, Wu Ming-hai, Zhang Kai, Wang Qiu-ping
Department of Otolaryngology-Head-Neck Surgery, Jinling Hospital, Nanjing University Medical School, Nanjing, 210002, China.
Tumour Biol. 2014 Jul;35(7):6303-9. doi: 10.1007/s13277-014-1828-x. Epub 2014 Mar 19.
Many studies have examined the association between the GSTM1 (null or non-null genotype) polymorphism and laryngeal cancer risk in various populations, but their results have been inconsistent. To assess this relationship more precisely, a meta-analysis was performed. PubMed was searched for case-control studies published up to December 2013. Data were extracted and pooled odds ratios (OR) with 95 % confidence intervals (CI) were calculated. Ultimately, 23 studies, comprising 2,562 laryngeal cancer cases and 4,091 controls, were included. Overall, for null versus present, the pooled OR was 1.22 (95 % CI = 1.10-1.36), and the heterogeneity was found in all studies. In the stratified analysis by ethnicity, significant risks were found among Asians (OR = 1.71; 95 % CI = 1.34-2.19; P = 0.011 for heterogeneity) and in Caucasians (OR = 1.13, 95 % CI = 1.00-1.27; P = 0.036 for heterogeneity). In conclusion, this meta-analysis demonstrates that the GSTM1 null gene polymorphism is an increased risk of laryngeal cancer in Asians and Caucasians.
许多研究已考察了谷胱甘肽硫转移酶M1(无效或非无效基因型)多态性与不同人群喉癌风险之间的关联,但其结果并不一致。为更精确地评估这种关系,进行了一项荟萃分析。检索了PubMed中截至2013年12月发表的病例对照研究。提取数据并计算合并比值比(OR)及95%置信区间(CI)。最终,纳入了23项研究,包括2562例喉癌病例和4091例对照。总体而言,无效基因型与有该基因型相比,合并OR为1.22(95%CI = 1.10 - 1.36),且所有研究中均存在异质性。在按种族进行的分层分析中,亚洲人(OR = 1.71;95%CI = 1.34 - 2.19;异质性P = 0.011)和高加索人(OR = 1.13,95%CI = 1.00 - 1.27;异质性P = 0.036)中发现了显著风险。总之,这项荟萃分析表明,谷胱甘肽硫转移酶M1无效基因多态性会增加亚洲人和高加索人患喉癌的风险。